Vaxxinova US
Company Information
At Vaxxinova, we develop, manufacture, and sell veterinary vaccines based upon our commitment to autogenous vaccines and our proprietary technologies. Vaxxinova provides patented Siderophore Receptors and Porins (SRP) technology and proprietary Newport Laboratories whole-cell autogenous biologics.
Proprietary whole-cell vaccine manufacturing is employed utilizing exclusive adjuvants unique to only Vaxxinova. Autogenous, often referred to as Custom Made Vaccines (CMVs), are manufactured with the attending veterinarian to address bacterial and viral pathogens.
SRP technology induces host immunity against cell wall components called Siderophore Receptors and Porins which transport iron. Iron to bacteria is like oxygen to humans. By creating antibodies to SRPs, the vaccine works by starving bacteria of an essential nutrient, causing it to die. Identical SRPs are highly conserved among a host of common bacteria.
Company History
In September, 2021, Vaxxinova US acquired Newport Laboratories from Boehringer Ingelheim. Newport had a very strong presence making autogenous (custom) vaccines for cattle and swine, as well as a state of the art diagnostic laboratory.
With complementary portfolios, the acquisition allowed for new synergies for producers and veterinarians.
VAXXINOVA US, INC. CONTINUES TO BE PRIVATELY HELD, AND HOLDS USDA ESTABLISHMENT LICENSE NO. 365 FOR THE MANUFACTURING OF VETERINARY BIOLOGICALS